New immunotherapy cocktail aims to outsmart kidney cancer
NCT ID NCT07000149
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This large global trial is testing whether two experimental drugs—volrustomig (an immunotherapy) and casdatifan (a pill)—work better than the current standard immunotherapy combination for people with advanced clear cell kidney cancer. About 1,100 participants who have not had prior treatment will be randomly assigned to one of the new combinations or the standard therapy. The study will measure how long people live without their cancer worsening and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Volrustomig (an immunotherapy drug) and Casdatifan (a pill that targets cancer cells)
What this could lead to
If successful, this could offer a new first-line treatment option for advanced kidney cancer that may be more effective than current standard therapy.
What could go wrong
This is an early-stage combination test; it may not prove better than existing treatments, and side effects from the new drugs could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
La Jolla, California, 92037, United States
-
Research Site
Aurora, Colorado, 80045, United States
-
Research Site
Boston, Massachusetts, 02215, United States
-
Research Site
New York, New York, 10065, United States
-
Research Site
Cleveland, Ohio, 44106, United States
-
Research Site
Nashville, Tennessee, 37232, United States
-
Research Site
Lubbock, Texas, 79430, United States
-
Research Site
East Melbourne, 3002, Australia
-
Research Site
Elizabeth Vale, 5112, Australia
-
Research Site
North Adelaide, 5000, Australia
-
Research Site
Syndey, 4032, Australia
-
Research Site
Beijing, 100142, China
-
Research Site
Guangzhou, 510060, China
-
Research Site
Nanjing, 2100008, China
-
Research Site
Nanning, 530021, China
-
Research Site
Shanghai, 200032, China
-
Research Site
Xiamen, 361003, China
-
Research Site
Batumi, 6010, Georgia
-
Research Site
Tbilisi, 0112, Georgia
-
Research Site
Tbilisi, 0114, Georgia
-
Research Site
Tbilisi, 0186, Georgia
-
Research Site
Busan, 48108, South Korea
-
Research Site
Seongnam-si, 13496, South Korea
-
Research Site
Seongnam-si, 13620, South Korea
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 06591, South Korea
-
Research Site
Seoul, 5505, South Korea
-
Research Site
Kaohsiung City, 833401, Taiwan
-
Research Site
Taichung, 404327, Taiwan
-
Research Site
Taichung, 40705, Taiwan
-
Research Site
Tainan, 704, Taiwan